- June 15, 2022Burlingame, Calif., June 15, 2022 — Inflammatix, Inc., a pioneering molecular diagnostics company, announced today the appointment of Purvesh Khatri, PhD,…
- November 30, 2021Burlingame, Calif., November 30, 2021 — Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as…
- November 18, 2021Third Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of…
- November 11, 2021Funding Will Support Groundbreaking Development of Sepsis Endotypes Test Burlingame, Calif., November 11, 2021 — Inflammatix, a pioneering molecular diagnostics company,…
- March 16, 2021Burlingame, Calif., March 16, 2021 — Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series…
- October 29, 2020Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of…
- September 29, 2020New Data Shows Inflammatix Machine Learning-Based Approach of Reading Immune System is Superior to IL-6 and Other Measures in Predicting…
- April 29, 2020Model Demonstrated Cost Effectiveness in Test Use on Patients Suspected of Acute Respiratory Tract Infections in American Emergency Department Setting…
- April 16, 2020Burlingame, Calif., April 16, 2020 — Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today…
- March 18, 2020Palo Alto, Calif., March 18, 2020 — 70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus…